Search Results for: Any combination instruments
drug application (nda) with the us fda before the end of pleasanton, ca, december th, . astex pharmaceuticals, inc., a wholly owned subsidiary of otsuka pharmaceutical co. ltd., based in tokyo, japan, today presented topline data from the ascertain phase trial of the orally administered fixed dose combination
chief of section of myelodysplastic syndromes, department of leukemia at the university of texas md anderson cancer center, houston, texas, on behalf of the study investigators. the study was designed as a randomized crossover study comparing oral astx ( mg cedazuridine and mg decitabine fixed dose combination...
https://astx.com/astex-pharmaceuticals-presents-topline-data-from-the-ascertain-phase-3-study-of-its-novel-oral-hypomethylating-agent-cedazuridine-and-decitabine-astx727-in-mds-and-cmml-at-the-american-society-of-h/